PriceTargets.com logo

NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.50
  • Forecasted Upside: 395.98 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.73 As of 01/19/2022 01:00 AM ET
▼ -0.02 (-0.53%)

This chart shows the closing price for AVEO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AVEO Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVEO

Analyst Price Target is $18.50
▲ +395.98% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for AVEO Pharmaceuticals in the last 3 months. The average price target is $18.50, with a high forecast of $19.00 and a low forecast of $18.00. The average price target represents a 395.98% upside from the last price of $3.73.

This chart shows the closing price for AVEO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in AVEO Pharmaceuticals. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2021SVB LeerinkReiterated RatingBuy$18.00Medium
7/12/2021HC WainwrightLower Price TargetBuy$27.00 ➝ $19.00High
3/17/2021HC WainwrightReiterated RatingBuyLow
3/11/2021SVB LeerinkBoost Price TargetOutperform$10.00 ➝ $18.00High
3/9/2021SVB LeerinkReiterated RatingBuyLow
1/19/2021SVB LeerinkBoost Price TargetOutperform$7.00 ➝ $10.00Medium
11/12/2020HC WainwrightReiterated RatingBuyMedium
11/9/2020Stifel NicolausInitiated CoverageBuy$9.00High
9/2/2020Piper SandlerReiterated RatingOverweight$26.00Low
8/13/2020SVB LeerinkInitiated CoverageOutperform$7.00High
6/1/2020HC WainwrightReiterated RatingBuy$10.00 ➝ $12.00High
5/29/2020Piper SandlerBoost Price TargetOverweight$18.50 ➝ $26.00High
5/29/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$15.00 ➝ $24.00High
5/1/2020HC WainwrightReiterated RatingBuy$6.00 ➝ $10.00High
4/1/2020Piper SandlerLower Price TargetOverweight$20.00 ➝ $18.50High
4/1/2020HC WainwrightReiterated RatingBuy$4.00 ➝ $6.00High
3/18/2020HC WainwrightBoost Price TargetBuy$1.75 ➝ $4.00High
11/4/2019Piper Jaffray CompaniesLower Price TargetOverweight$40.00 ➝ $20.00High
10/1/2019HC WainwrightReiterated RatingBuy$17.50Medium
9/11/2019HC WainwrightUpgradeNeutral ➝ Buy$10.00 ➝ $17.50Medium
9/10/2019Piper Jaffray CompaniesBoost Price TargetOverweight$30.00 ➝ $40.00High
3/28/2019National SecuritiesInitiated CoverageSellHigh
3/18/2019HC WainwrightReiterated RatingHold$10.00High
2/4/2019B. RileyReiterated RatingBuy ➝ Neutral$50.00 ➝ $10.00High
2/1/2019HC WainwrightDowngradeBuy ➝ Neutral$10.00High
1/31/2019Piper Jaffray CompaniesReiterated RatingOverweight$50.00 ➝ $30.00High
1/14/2019HC WainwrightReiterated RatingBuy$90.00High
1/8/2019B. RileyInitiated CoverageBuy$50.00Low
1/3/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$30.00High
12/20/2018FBR & Co.Set Price TargetBuy$30.00Medium
12/13/2018HC WainwrightSet Price TargetBuy$90.00High
11/6/2018National SecuritiesDowngradeBuy ➝ NeutralHigh
11/6/2018HC WainwrightSet Price TargetBuy ➝ Buy$90.00High
10/23/2018HC WainwrightSet Price TargetBuy$70.00High
8/16/2018HC WainwrightInitiated CoverageBuy$65.00Medium
1/16/2018B. RileyReiterated RatingBuy$50.00High
11/13/2017B. RileyInitiated CoverageBuy ➝ Buy$50.00N/A
8/28/2017Piper Jaffray CompaniesBoost Price TargetOverweight$38.00 ➝ $45.00High
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00Low
7/13/2017FBR & Co.Reiterated RatingOutperform$30.00High
6/30/2017FBR & Co.Reiterated RatingBuy$30.00Low
6/24/2017Piper Jaffray CompaniesSet Price TargetBuy$20.00High
6/23/2017Piper Jaffray CompaniesReiterated RatingPositiveHigh
5/22/2017FBR & Co.Reiterated RatingOutperform$30.00High
4/17/2017FBR & Co.Reiterated RatingOutperform$30.00High
4/8/2017FBR & Co.Reiterated RatingBuyLow
3/25/2017FBR & Co.Reiterated RatingOutperform$30.00Medium
2/27/2017FBR & Co.Reiterated RatingOutperform$30.00N/A
(Data available from 1/20/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/20/2022

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

AVEO Pharmaceuticals logo
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $3.73
Low: $3.72
High: $3.82

50 Day Range

MA: $5.40
Low: $3.73
High: $7.40

52 Week Range

Now: $3.73
Low: $3.72
High: $18.24

Volume

209,920 shs

Average Volume

436,021 shs

Market Capitalization

$128.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of AVEO Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on AVEO Pharmaceuticals in the last twelve months: HC Wainwright, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for AVEO.

What is the current price target for AVEO Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for AVEO Pharmaceuticals in the last year. Their average twelve-month price target is $18.50, suggesting a possible upside of 396.0%. HC Wainwright has the highest price target set, predicting AVEO will reach $19.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $18.00 for AVEO Pharmaceuticals in the next year.
View the latest price targets for AVEO.

What is the current consensus analyst rating for AVEO Pharmaceuticals?

AVEO Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVEO will outperform the market and that investors should add to their positions of AVEO Pharmaceuticals.
View the latest ratings for AVEO.

What other companies compete with AVEO Pharmaceuticals?

Other companies that are similar to AVEO Pharmaceuticals include Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Biogen, Seagen, Alnylam Pharmaceuticals, Incyte, BioMarin Pharmaceutical, Exact Sciences, Repligen, United Therapeutics, Novavax, Neurocrine Biosciences and Arena Pharmaceuticals.

How do I contact AVEO Pharmaceuticals' investor relations team?

AVEO Pharmaceuticals' physical mailing address is 30 WINTER STREET, BOSTON MA, 02108. The biopharmaceutical company's listed phone number is (617) 400-0101 and its investor relations email address is [email protected] The official website for AVEO Pharmaceuticals is www.aveooncology.com.